Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sri Lanka Set To Disclose Results Of Rubella Vaccine Probe

This article was originally published in PharmAsia News

Executive Summary

Sri Lanka's Health Ministry is set to issue a report on the safety of a rubella vaccine used in a national inoculation program tied to the death of one child and serious complications among others. Experts from the World Health Organization are expected to look into the matter and recommend whether the suspended program to vaccinate 400,000 children by the end of November should be resumed. At least two government investigations have been conducted into the vaccine and instruments used to deliver it. The Public Health Services that conducted the investigations issued its interim report to the Health Ministry March 20. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071148

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel